[Corneal toxicity of mirvetuximab soravtansine: A case report]

J Fr Ophtalmol. 2022 Jun;45(6):e263-e264. doi: 10.1016/j.jfo.2021.10.012. Epub 2022 Feb 8.

[Article in French]

Authors

L Vuillemey¹, P Goin¹, E Kalbacher², F Bazan², V Gay¹, B Delbosc¹, A-S Gauthier³

Affiliations

¹ Service d'ophtalmologie, CHU de Besançon, 3, boulevard Fleming, 25000 Besançon, France.
² Service d'oncologie, CHU de Besançon, 3, boulevard Fleming, 25000 Besançon, France.
³ Service d'ophtalmologie, CHU de Besançon, 3, boulevard Fleming, 25000 Besançon, France; Inserm, EFS BFC, UMR 1098, université Bourgogne Franche-Comté, 25030 Besançon, France. Electronic address: asophiegauthier@yahoo.fr.

PMID: 35148904
DOI: 10.1016/j.jfo.2021.10.012

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Immunoconjugates*
Maytansine* / adverse effects
Maytansine* / analogs & derivatives

Substances

Antibodies, Monoclonal, Humanized
Immunoconjugates
Maytansine
mirvetuximab soravtansine